Psyence Biomedical (NASDAQ:PBM) Issues Earnings Results

Psyence Biomedical (NASDAQ:PBM) announced its quarterly earnings data on Monday. The company reported ($0.40) EPS for the quarter, FiscalAI reports.

Psyence Biomedical Stock Down 1.6%

PBM traded down $0.05 during trading on Monday, hitting $3.10. 32,512 shares of the company traded hands, compared to its average volume of 1,506,986. The firm has a market cap of $3.16 million, a P/E ratio of 0.12 and a beta of 1.65. Psyence Biomedical has a one year low of $1.92 and a one year high of $74.94. The stock’s fifty day moving average is $4.86 and its 200 day moving average is $4.63.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Psyence Biomedical stock. Virtu Financial LLC boosted its holdings in Psyence Biomedical Ltd. (NASDAQ:PBM) by 258.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,042 shares of the company’s stock after acquiring an additional 26,717 shares during the quarter. Virtu Financial LLC owned 3.63% of Psyence Biomedical worth $28,000 at the end of the most recent reporting period. Institutional investors own 77.44% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Psyence Biomedical to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Psyence Biomedical in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Psyence Biomedical presently has a consensus rating of “Sell”.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.